Drug intelligence / Profile preview

WSK-V104

Development stage: Preclinical
Lead developer: WestVac Biopharma
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**WSK-V104** is an adjuvanted recombinant trivalent influenza vaccine jointly developed by WestVac Biopharma and West China Hospital of Sichuan University for prevention of seasonal influenza. The vaccine is produced using an insect cell-baculovirus recombinant protein expression system rather than egg-based influenza-virus cultivation and is designed to match World Health Organization-recommended trivalent seasonal influenza strains. WestVac states that the product incorporates the novel adjuvant WGa01 to enhance and prolong vaccine-induced protective immune responses. WSK-V104 received National Medical Products Administration clinical-trial authorization in China on February 9, 2026.

Other names: Recombinant trivalent influenza vaccine

Beyond the preview

Go deeper on WSK-V104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V104.

Explore the full profile